Are Options Traders Betting on a Big Move in Iovance Biotherapeutics (IOVA) Stock?Zacks Investment Research • 03/11/20
Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with LifileucelGlobeNewsWire • 01/15/20
Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 AnalogGlobeNewsWire • 01/12/20
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License AgreementGlobeNewsWire • 01/12/20
Iovance Biotherapeutics Announces Results of a Subgroup Analysis of Patients in the Lifileucel Metastatic Melanoma Study who are Primary Refractory to Anti-PD-1/L1 TherapyGlobeNewsWire • 11/21/19
Iovance Biotherapeutics' (IOVA) CEO Maria Fardis on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/05/19
TIL Death Do Us Part: CAR T History Foreshadows Iovance's Destiny For OutperformanceSeeking Alpha • 10/02/19
Iovance Biotherapeutics Announces Four Abstracts to be Presented at the Upcoming 2019 SITC Annual MeetingGlobeNewsWire • 10/02/19